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Genetic influences on psychiatric disorders transcend diagnostic boundaries, 
suggesting substantial pleiotropy of contributing loci. However, the nature and 
mechanisms of these pleiotropic effects remain unclear. We performed analyses of 
232,964 cases and 494,162 controls from genome-wide studies of anorexia nervosa, 
attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major 
depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome. 
Genetic correlation analyses revealed a meaningful structure within the eight disorders, 
identifying three groups of inter-related disorders. Meta-analysis across these eight 
disorders detected 109 loci associated with at least two psychiatric disorders, including 
23 loci with pleiotropic effects on four or more disorders and 11 loci with antagonistic 
effects on multiple disorders. The pleiotropic loci are located within genes that show 
heightened expression in the brain throughout the lifespan, beginning prenatally in the 
second trimester, and play prominent roles in neurodevelopmental processes. These 
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Psychiatric disorders affect more than 25% of the population in any given year and are 
a leading cause of worldwide disability (Global Burden of Disease Injury Incidence 
Prevalence Collaborators, 2017; Kessler and Wang, 2008).  The substantial influence of 
genetic variation on risk for a broad range of psychiatric disorders has been established 
by both twin and, more recently, large-scale genomic studies (Smoller et al., 2018). 
Psychiatric disorders are highly polygenic, with a large proportion of heritability 
contributed by common variation. Many risk loci have emerged from genome-wide 
association studies (GWAS) of, among others, schizophrenia (SCZ), bipolar disorder 
(BIP), major depression (MD), and attention-deficit/hyperactivity disorder (ADHD) from 
the Psychiatric Genomics Consortium (PGC) and other efforts (Sullivan et al., 2018). 
These studies have revealed a surprising degree of genetic overlap among psychiatric 
disorders (Brainstorm Consortium, 2018; Cross-Disorder Group of the Psychiatric 
Genomics Consoritum, 2013). Elucidating the extent and biological significance of 
cross-disorder genetic influences has implications for psychiatric nosology, drug 
development, and risk prediction. In addition, characterizing the functional genomics of 
cross-phenotype genetic effects may reveal fundamental properties of pleiotropic loci 
that differentiate them from disorder-specific loci, and help identify targets for 
diagnostics and therapeutics.  
In 2013, analyses by the PGC’s Cross-Disorder Group identified loci with 
pleiotropic effects across five disorders: autism spectrum disorder (ASD), ADHD, SCZ, 
BIP, and MD in a sample comprising 33,332 cases and 27,888 controls (Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013). In the current study, we 
examined pleiotropic effects in a greatly expanded dataset, encompassing 232,964 
cases and 494,162 controls, that included three additional psychiatric disorders: 
Tourette syndrome (TS), obsessive-compulsive disorder (OCD), and anorexia nervosa 
(AN). We address four major questions regarding the shared genetic basis of these 
eight disorders: 1) Can we identify a shared genetic structure within the broad range of 
these clinically distinct psychiatric disorders? 2) Can we detect additional loci 
associated with risk for multiple disorders (pleiotropic loci)? 3) Do some of these risk loci 
have opposite allelic effects across disorders? and 4) Can we identify functional 




RESULTS   
  
We analyzed genome-wide single nucleotide polymorphism (SNP) data for eight 
neuropsychiatric disorders using a combined sample of 232,964 cases and 494,162 
controls (Table 1; Table S1). The eight disorders included AN (Duncan et al., 2017) 
ASD (Grove et al., 2019a), ADHD (Demontis et al., 2019), BIP (Stahl et al., 2019), MD 
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(Wray et al., 2018), OCD (International Obsessive Compulsive Disorder Foundation 
Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association 
Studies (OCGAS), 2018), TS (Yu et al., 2019), and SCZ (Schizophrenia Working Group 
of the Psychiatric Genomics, 2014). All study participants were of self-identified 
European ancestry, which was supported by principal component analysis of genome-
wide data.   
 
Genetic correlations among eight neuropsychiatric disorders indicate three 
genetic factors.  
After standardized and uniform quality control, additive logistic regression analyses 
were performed on individual disorders (Online Methods). 6,786,993 SNPs were 
common across all datasets and were retained for further study. Using the summary 
statistics of these SNPs, we first estimated pairwise genetic correlations among the 
eight disorders using linkage disequilibrium (LD) score regression analyses (Bulik-
Sullivan et al., 2015) (Online Methods; Fig. 1a; Table S2.1). The results were broadly 
concordant with previous estimates (Brainstorm Consortium, 2018; Cross-Disorder 
Group of the Psychiatric Genomics Consoritum, 2013). The genetic correlation was 
highest between SCZ and BIP (rg = 0.70 ±0.02), followed by OCD and AN (rg = 0.50 
±0.12). Interestingly, based on genome-wide genetic correlations, MD was closely 
correlated with ASD (rg=0.45 ±0.04) and ADHD (rg=0.44 ±0.03), two childhood-onset 
disorders. Despite variation in magnitude, significant genetic correlations were apparent 
for most pairs of disorders, suggesting a complex, higher-order genetic structure 
underlying psychopathology (Fig. 1b).   
  
We modeled the genome-wide joint architecture of the eight neuropsychiatric disorders 
using an exploratory factor analysis (EFA) (Gorsuch, 1988), followed by genomic 
structural equation modeling (SEM) (Grotzinger et al., 2019) (Online Methods; Fig. 1c). 
EFA identified three correlated factors, which together explained 51% of the genetic 
variation in the eight neuropsychiatric disorders (Table S2.2). The first factor consisted 
primarily of disorders characterized by compulsive/perfectionistic behaviors, specifically 
AN, OCD, and, more weakly, TS. The second factor was characterized by mood and 
psychotic disorders (MD, BIP, and SCZ), and the third factor by three early-onset 
neurodevelopmental disorders (ASD, ADHD, TS) as well as MD. Similar to our EFA 
results, hierarchical clustering analyses also identified three sub-groups among the 
eight disorders (Data S1.1). Based on extensive follow-up analyses, this genetic 
correlational structure does not appear to be biased by sample overlap or sample size 
differences among the eight disorders (Data S1.2-1.4).   
   
Cross-disorder meta-analysis identifies 109 pleiotropic loci  
The factor structure described above is based on average effects across the genome, 
but does not address more fine-grained cross-disorder effects at the level of genomic 
regions or individual loci. To identify genetic loci with shared risk, we performed a meta-
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analysis of the eight neuropsychiatric disorders using a fixed-effects-based method 
(Bhattacharjee et al., 2012) that accounts for the differences in sample sizes, existence 
of subset-specific effects, and overlapping subjects across datasets (Online Methods). 
The standardized genomic inflation factor was close to one, suggesting no inflation of 
test statistics due to confounding (λ1000 = 1.005; Fig. 2a). We identified 136 LD-
independent regions with genome-wide significant association (Pmeta ≤ 5x10-8). Due to 
the extensive LD at the major histocompatibility complex (MHC) region (chromosome 6 
region at 25-35 Mb), we considered multiple signals present there as one locus. 101 of 
the 136 (74.3%) significantly associated regions overlapped with previously reported 
genome-wide significant regions from at least one individual disorder, while 35 loci 
(25.7%) represented novel genome-wide significant associations. Simulation analyses 
confirmed that the number of pleiotropic loci we identified exceeds chance expectation 
given the sample size and genetic correlations among the eight disorders (p < 9.9x10-3; 
Data S1.5; for further details, see Online Methods).  
  
Within these 136 loci, multi-SNP-based conditional analysis (Yang et al., 2012) 
identified 10 additional SNPs with independent associations, resulting in a total of 146 
independent lead SNPs (Table S3.1). To provide a quantitative estimate of the best fit 
configuration of cross-disorder genotype-phenotype relationships, we estimated the 
posterior probability of association (referred to as the m-value) with each disorder using 
a Bayesian statistical framework (Han and Eskin, 2012) (Online Methods; Table S3.2) 
As recommended (Han and Eskin, 2012), an m-value threshold of 0.9 was used to 
predict with high confidence that a particular SNP was associated with a given disorder. 
Also, m-values of < 0.1 were taken as strong evidence against association. Plots of the 
SNP p-value vs. m-value for all 146 lead SNPs are shown in Data S2. Nearly 75% 
(109/146) of the genome-wide significant SNPs were pleiotropic (i.e., associated with 
more than one disorder). As expected, configurations of disease association reflected 
the differences in the statistical power and genetic correlations between the samples 
(Fig. S1). Of the 109 pleiotropic loci, 83% and 72% involved SCZ and BIP, respectively. 
MD, which had the largest case-control sample, was associated with 48% of the 
pleiotropic loci (N=52/109). Despite the relatively small sample size, ASD was 
implicated in 36% of the pleiotropic loci. Most of the ASD associations co-occurred with 
SCZ and BIP. The other disorders, ADHD, TS, OCD, and AN featured associations in 
16%, 14%, 11%, and 7% of the pleiotropic loci, respectively. Of the single-disorder-
specific loci, 81% and 16% were associated with SCZ and MD, respectively.  
  
Table 2 summarizes 23 pleiotropic loci associated with at least four of the disorders. 
Among these loci, heterogeneity of effect sizes was minimal (p-value of Q > 0.1). Eleven 
of the 23 lead SNPs map to the intron of a protein-coding gene, and seven additional 
lead SNPs had at least one protein-coding gene within 100 kb. We used an array of 
functional genomics resources, including brain eQTL and Hi-C data (Wang et al., 2018; 
Won et al., 2016) to prioritize potential candidate genes to the identified regions (Online 
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Methods; Fig. 2b). The Manhattan plot in Fig. 2c highlights some of the prioritized 
candidate genes.   
 
Of the 109 risk loci with shared effects, the 18q21.2 region surrounding SNP rs8084351 
at the netrin 1 receptor gene DCC featured the most pleiotropic association (Pmeta = 
4.26 x 10-12; Fig. 3a). This region showed association with all eight psychiatric 
disorders, and has been previously associated with both MD and neuroticism  
(Turley et al., 2018; Wray et al., 2018). The signal in our meta-analysis colocalizes with 
brain eQTLs for DCC (eQTL association FDR q = 2.27 x 10-5), supporting DCC as a 
plausible candidate gene (Fig. S2). The product of DCC plays a key role in guiding 
axonal growth during neurodevelopment and serves as a master regulator of midline 
crossing and white matter projections (Bendriem and Ross, 2017). Gene expression 
data indicate that DCC expression peaks during early prenatal development (Fig. S3).   
 
The second most pleiotropic locus in our analysis was identified in an intron of RBFOX1 
(RNA Binding Fox-1 Homolog 1) on 16p13.3 (lead SNP rs7193263; Pmeta = 5.59 x 10-11). 
The lead SNP showed association with all of the disorders except AN (Fig. 3b). 
RBFOX1 (also called A2BP1) encodes a splicing regulator mainly expressed in neurons 
and known to target several genes important to neuronal development, including NMDA 
receptor 1 and voltage-gated calcium channels (Gandal, 2018; Gehman, 2011; Hamada 
et al., 2015). Knock-down and silencing of RBFOX1 during mouse corticogenesis 
impairs neuronal migration and synapse formation (Hamada et al., 2015; Hamada et al., 
2016), implying its pivotal role in early cortical maturation. In contrast to DCC, however, 
developmental gene-expression of RBFOX1 showed gradually increasing gene 
expression throughout the prenatal period (Fig. S3). Animal models and association 
studies have implicated RBFOX1 in aggressive behaviors, a trait observed in several of 
the disorders in our analysis (Fernandez-Castillo et al., 2017). 
  
Of the 109 pleiotropic loci, 76 were identified in the GWAS of individual disorders, while 
the remaining 33 are novel. The most pleiotropic among these novel loci was a region 
downstream of NOX4 (NADPH Oxidase 4) that was associated with SCZ, BIP, MD, 
ASD, and AN (rs117956829; Pmeta = 1.82 x 10-9; Fig. 3c). Brain Hi-C data (Wang et al., 
2018; Won et al., 2016) detected a direct interaction of the cross-disorder association 
region with NOX4 in both adult and fetal brain (interaction p=3.2x10-16 and 9.3x10-6, 
respectively). As a member of the family of NOX genes that encode subunits of NADPH 
oxidase, NOX4 is a major source of superoxide production in human brain and a 
promoter of neural stem cell growth (Kuroda et al., 2014; Topchiy et al., 2013). 
  
Figure 3d illustrates another novel psychiatric risk locus associated with SCZ, BIP, 
ASD, and OCD (Pmeta = 3.58 x 10-8). The lead SNP rs10265001 resides between 
MRPS33 (Mitochondrial Ribosomal Protein S33) and BRAF (B-Raf Proto-Oncogene, 
Serine/Threonine Kinase) on 7q34. The brain Hi-C data indicated interaction of the 
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associated region with the promoters of two nearby genes: BRAF, which contributes to 
the MAP kinase signal transduction pathway and plays a role in postsynaptic responses 
of hippocampal neurons (Grantyn and Grantyn, 1973), and KDM7A (encoding Lysine 
Demethylase 7A), which plays a central role in the nervous system and midbrain 
development (Horton et al., 2010; Qi et al., 2010; Tsukada et al., 2010).      
 
Our prior cross-disorder meta-analysis of five psychiatric disorders (Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013) found no evidence of SNPs with 
antagonistic effects on two or more disorders. Here, we examined whether any variants 
with meta-analysis p ≤ 1x10-6 had opposite directional effects between disorders (Online 
Methods). After adjusting for having examined 206 loci across eight disorders (q < 
0.001), we identified 11 loci with evidence of opposite directional effects on two or more 
disorders (Fig. 4; Table S3.3). The disorder configuration of opposite directional effects 
varied for the 11 loci, including three loci with opposite directional effects on SCZ and 
MD (rs301805, rs1933802, rs3806843), two loci between SCZ and ASD (rs9329221, 
rs2921036), and one locus (rs75595651) with opposite directional effects on the two 
mood disorders, BIP and MD. Notably, all of the six loci involving SCZ and BIP exhibited 
the same directional effect on the two disorders (Pbinom < 0.05), in line with their strong 
genome-wide genetic correlation.    
 
Functional characterization of pleiotropic risk loci   
  
We conducted a series of bioinformatic analyses that examined whether loci with 
shared risk effects on multiple neuropsychiatric disorders had characteristic features 
that distinguished them from non-pleiotropic risk loci. First, we annotated the functional 
characteristics of 146 lead SNPs using various public data sources (Online Methods; 
Tables S4). Overall, they showed significant enrichment of genes expressed in the 
brain (beta=0.123, SE=0.0109, enrichment p = 1.22x10-29) and pituitary (beta=0.0916, 
SE=0.0136, p = 8.74 x 10-12), but not in the other Genotype-Tissue Expression (GTEx) 
tissues. (Table S5.1; Fig. 5a). A separate analysis of 109 pleiotropic risk loci also 
showed specific enrichment of genes expressed in multiple brain tissues (p = 1.55 x 10-
5; Table S5.2), while disorder-specific loci showed nominally enriched brain gene 
expression in the cortex (p =2.14 x 10-2; Table S5.3).   
 
Gene-set enrichment analyses using Gene Ontology data suggested involvement of 
pleiotropic risk loci in neurodevelopmental processes (Table S6.1). The 109 pleiotropic 
risk loci were enriched for genes involved in neurogenesis (gene-set enrichment p = 
9.67 x 10-6), regulation of nervous system development (p = 3.41 x 10-5), and neuron 
differentiation (p = 3.30 x 10-5), while enrichment of these gene-sets was not seen for 
the 37 disorder-specific risk loci (adjusted enrichment p > 0.05; Table S6.2). Pleiotropic 
risk loci also showed enrichment of genes involved in specific neurotransmitter-related 
pathways -- glutamate receptor signaling (p = 2.45 x 10-6) and voltage-gated calcium 
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channel complex (p = 5.72 x 10-4) -- while non-pleiotropic risk loci, which were 
predominantly SCZ-associated, were over-represented among acetylcholine receptor 
genes (p = 7.25 x 10-8). Analysis of cortical gene expression data also suggested 
enrichment of pleiotropic risk genes in cortical glutamatergic neurons through layers 2-6 
(Table S6.3), further supporting the shared role of glutamate receptor signaling in the 
pathogenesis of diverse neuropsychiatric disorders.  
 
In contrast to the differences in neuronal development and neuronal signaling pathways, 
pleiotropic and non-pleiotropic risk loci shared several characteristics related to genomic 
function. For instance, gene-set enrichment analyses indicated that both pleiotropic and 
non-pleiotropic risk loci were enriched for genes involved in the regulation of synaptic 
plasticity, neurotransmission, and synaptic cellular components. More than 41% of the 
genes associated with our genome-wide significant loci, both pleiotropic and non-
pleiotropic, were intolerant of loss of function mutations (pLI score ≥ 0.9); this is highly 
unlikely to occur by chance (Fisher’s exact p=4.90x10-8). This finding was consistent 
when examining pleiotropic (p=2.85x10-11) and non-pleiotropic risk loci (p=1.56x10-3) 
separately.        
 
Next, we compared spatio-temporal gene-expression patterns for the 109 pleiotropic 
risk loci and the 37 disorder-specific loci using post-mortem brain data. On average, 
disorder-specific and pleiotropic risk loci showed a similar level of gene expression in 
both prenatal and postnatal development after multiple testing correction (t-test p > 
0.025 x10-2; Fig. S4). During prenatal development, non-pleiotropic loci (mainly SCZ-
associated) showed peak expression in the first trimester, after which expression rapidly 
decreased, while pleiotropic genes associated with only 2 disorders (“pleiotropy=2”; 60 
loci) and those associated with more than 2 (“pleiotropy>2”, 49 loci) showed peak 
expression around the second trimester (Fig. 5b). After birth, all three groups showed 
gradually increasing gene expression until adulthood. Expression levels were 
associated with the degree of pleiotropy, with the pleiotropy>2 group showing higher 
gene expression than either the pleiotropy=2 group (t-test p < 2.10x10-4) or non-
pleiotropic risk loci (t-test p < 2.2x10-16).      
  
Enrichment analyses using the genes preferentially expressed in specific cortical 
regions suggested that pleiotropic loci were over-represented among genes expressed 
in the frontal cortex, while non-pleiotropic loci were enriched in the occipital cortex (FDR 
q<0.05; Fig. 5c). Cell-type-specific analysis indicated that genes implicated in 
pleiotropic loci were mainly expressed in neurons (FDR q<0.05) but not in glial cell 
types. Further, enrichment of pleiotropic loci in neuronal cells was also associated with 
the degree of pleiotropy, as highlighted in Fig. 5d.   
  
Previous studies of model organisms using gene knock-out experiments suggested that 
pleiotropic risk loci may undergo stronger selection than non-pleiotropic loci (Hill and 
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Zhang, 2012). However, we found no evidence that pleiotropic risk variants are under 
stronger evolutionary constraints (Table S6.4). Various comparative genomics 
resources, including PhyloP (Pollard et al., 2010), PhastCons (Siepel et al., 2005), and 
GERP++ (Davydov et al., 2010), showed our top loci to have similar properties 
regardless of the extent of pleiotropy. Neither did we find differences between disorder-
specific lead SNPs and pleiotropic SNPs with respect to their minor allele frequencies, 
average heterozygosity, or predicted allele ages (Kiezun et al., 2013). Pleiotropic and 
non-pleiotropic SNPs also did not differ in terms of the distance to nearest genes, 
distance to splicing sites, chromosome compositions, and predicted functional 
consequences of non-coding regulatory elements.   
 
Relationship between cross-disorder genetic risk and other brain-related traits 
and diseases   
To explore the genetic relationship of cross-disorder genetic risk with other traits, we 
treated this 8-disorder GWAS meta-analysis as a single “cross-disorder phenotype.” We 
applied LDSC to estimate SNP heritability (h2SNP) and genetic correlations with other 
phenotypes, using block jackknife-based standard errors to estimate statistical 
significance. The estimated h2SNP of the cross-disorder phenotype was 0.146 (SE 
0.0058; observed scale). Using data for 25 brain-related traits selected from LDHub 
(Zheng et al., 2017), we found significant genetic correlations of the cross-disorder 
phenotype with seven traits (at a FDR-corrected p-value threshold 0.002): never/ever 
smoking status, years of education, neuroticism, subjective well-being, and three sleep-
related phenotypes (chronotype, insomnia, and excessive daytime sleepiness) (Table 
S7.1).  
  
GWAS catalog data for the 109 pleiotropic risk loci showed enrichment of implicated 
genes in a range of brain-related traits (Table S7.2). As expected, the associated traits 
included SCZ, BIP, and ASD. In addition, the pleiotropic risk loci were enriched among 
genes previously associated with neuroticism (corrected enrichment p= 5.28x10-6; 
GRIK3, CTNND1, DRD2, RGS6, RBFOX1, ZNF804A, L3MBTL2, CHADL, RANGAP1, 
RSRC1, GRM3), cognitive ability (corrected p= 7.15x10-5; PTPRF, NEGR1, ELOVL3, 
SORCS3, DCC, CACNA1I), and night sleep phenotypes (corrected p= 1.86x10-2; PBX1, 
NPAS3, RGS6, GRIN2A, MYO18A, TIAF1, CNTN4, PPP2R2B, TENM2, CSMD1). We 
also found significant enrichment of pleiotropic risk genes in multiple measures of body 
mass index (BMI), supporting previous studies suggesting a shared etiologic basis 
between a range of neuropsychiatric disorders and obesity (Hartwig et al., 2016; 
Lopresti and Drummond, 2013; Milaneschi et al., 2018).  
 
 
DISCUSSION   
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In the largest cross-disorder GWAS meta-analysis of neuropsychiatric disorders to date, 
comprising more than 725,000 cases and controls across eight disorders, we identified 
146 LD-independent lead SNPs associated with at least one disorder, including 35 
novel loci. Of these, 109 loci were found to affect two or more disorders, although 
characterization of this pleiotropy is partly dependent on per-disorder sample size. Our 
results provide five major insights into the shared genetic basis of psychiatric disorders.  
  
First, modeling of genetic correlations among the eight disorders using two different 
methods (EFA and hierarchical clustering) identified three groups of disorders based on 
shared genomics: one comprising disorders characterized by compulsive behaviors 
(AN, OCD and TS), a second comprising mood and psychotic disorders (MD, BIP and 
SCZ), and a third comprising two early-onset neurodevelopmental disorders (ASD and 
ADHD) and one disorder each from the first two factors (TS and MD). The loading of 
MD on two factors may reflect biological heterogeneity within MD, consistent with recent 
evidence showing that early-onset depression is associated with genetic risk for ADHD 
and with neurodevelopmental phenotypes (Rice et al., 2018). Overall, these results 
indicate a substantial pairwise genetic correlation between multiple disorders along with 
a higher-level genetic structure that point to broader domains underlying genetic risk to 
psychopathology. These findings are at odds with the classical, categorical classification 
of mental illness.   
  
Second, variant-level analyses support the existence of substantial pleiotropy, with 
nearly 75% of the 146 genome-wide significant SNPs influencing more than one of the 
eight examined disorders. We also identified a set of 23 loci with particularly extensive 
pleiotropic profiles, affecting four or more disorders. The most highly pleiotropic locus in 
our analyses, with evidence of association with all eight disorders, maps within DCC, a 
gene fundamental to the early development of white matter connections in the brain 
(Bendriem and Ross, 2017). Prior studies showed that DCC is a master regulator of 
axon guidance (through its interactions with netrin-1 and draxin (Liu et al., 2018). Loss 
of function mutations in DCC cause severe neurodevelopmental syndromes involving 
loss of midline commissural tracts and diffuse disorganization of white matter tracts 
(Bendriem and Ross, 2017; Jamuar et al., 2017; Marsh et al., 2017). A highly pleiotropic 
effect of variation in DCC on diverse psychiatric disorders with childhood and 
adolescent onset would be consistent with its role in both early organization of neuronal 
circuits and the maturation of mesolimbic dopaminergic connections to the prefrontal 
cortex during adolescence (Hoops and Flores, 2017; Reynolds et al., 2018; Vosberg et 
al., 2018).   
  
Third, we identified a set of loci that have opposite effects on risk of psychiatric 
disorders.  Notably, these included loci with opposing effects on pairs of disorders that 
are genetically correlated and have common clinical features. For example, a SNP 
within MRSA was associated with opposing effects on two neurodevelopmental 
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disorders (ASD and SCZ), and a variant within KIAA1109 had opposite directional 
effects on major mood disorders (BIP and MD) (Table S3.3). These results underscore 
the complexity of genetic relationships among related disorders and suggest that overall 
genetic correlations may obscure a more complex set of genetic relationships at the 
level of specific loci and pathways, as seen in immune-mediated diseases (Baurecht et 
al., 2015; Lettre and Rioux, 2008; Schmitt et al., 2016). This heterogeneity of effects 
between genetically correlated disorders is also consistent with a recent analysis that 
revealed loci contributing to biological differences between BIP and SCZ and found 
polygenic risk score associations with specific symptom dimensions (Bipolar Disorder 
and Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2018). A 
complete picture of cross-phenotype genetic relationships will require understanding 
both same and opposite directional effects. In addition, to the extent that pleiotropic loci 
may reveal targets for drug discovery, opposite directional effects on psychiatric 
disorders could help anticipate problematic off-target effects.  
  
Fourth, we found extensive evidence that neurodevelopmental effects underlie the 
cross-disorder genetics of mental illness. In addition to DCC, a link between pleiotropy 
and genetic effects on neurodevelopment was also seen for other top loci in our 
analysis, including RBFOX1, BRAF, and KDM7A, all of which have been shown in prior 
research to influence aspects of nervous system development. Gene enrichment 
analyses showed that pleiotropic loci were distinguished from disorder-specific loci by 
their involvement in neurodevelopmental pathways including neurogenesis, regulation 
of nervous system development, and neuron differentiation. These results are 
consistent with those of a smaller recent analysis in the population-based Danish 
iPSYCH cohort (comprising 46,008 cases and 19,526 controls across six 
neuropsychiatric disorders) (Schork et al., 2019). In that analysis, consistent with the 
present findings, functional genomic characterization of cross-disorder loci implicated 
fetal neurodevelopmental processes, with greater prenatal than postnatal expression. In 
addition, SORCS3 emerged as a genome-wide significant cross-disorder locus in both 
studies. However, other specific loci, cell types, and pathways implicated in the iPSYCH 
analysis differed from those identified in our study. In supplementary analyses, we did 
not find evidence of significant overrepresentation of genes related to pleiotropic SNPs 
identified here among previously defined genomic disorder regions or genes associated 
with neurodevelopmental disorders from rare variant studies (including ASD, intellectual 
disability, and developmental delay) (Samocha et al., 2017; Satterstrom et al., 2019) 
(Data S3.1-3.3). 
  
Fifth, our analyses of spatiotemporal gene expression profiles revealed that pleiotropic 
loci are enriched among genes expressed in neuronal cell types, particularly in frontal or 
prefrontal regions. They also demonstrated a distinctive feature of genes related to 
pleiotropic loci: compared with disorder-specific loci, they are on average expressed at 
higher levels both prenatally and postnatally (Figure 5). More specifically, single-
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disorder (mainly SCZ) loci were related to genes that were preferentially expressed in 
the first fetal trimester followed by a decline over the prenatal period and then relatively 
stable levels postnatally. In contrast, average expression of genes related to pleiotropic 
loci peaked in the second trimester and remained overexpressed throughout the 
lifespan. When dividing the pleiotropic loci into bins of those associated with two 
disorders (mainly SCZ and BIP) vs. three or more disorders, we observed a consistent 
gradient of greater expression associated with broader pleiotropy. These results are 
based on average expression profiles, and not all individual gene expression patterns 
follow this pattern. 
  
Taken together, our results suggest that pleiotropic loci appear to be distinguished by 
both their differential importance in neurodevelopmental processes and their heightened 
brain expression after the first trimester. Apart from this, however, pleiotropic loci were 
similar to non-pleiotropic loci across a range of other functional features, including 
intolerance to loss-of-function mutations, evidence of selection, minor allele frequencies, 
and genomic position relative to functional elements.     
  
Overall, our results identify a range of pleiotropic effects among loci associated with 
psychiatric disorders. Consistent with prior research (Brainstorm Consortium, 2018; 
Cross-Disorder Group of the Psychiatric Genomics Consoritum, 2013), we found 
substantial pairwise genetic correlations across child- and adult-onset disorders and 
extended these findings by demonstrating clusters of genetically-related disorders. 
These results augment a substantial body of research demonstrating that genetic 
influences on psychopathology do not map cleanly onto the clinical nosology 
instantiated in the DSM or ICD (Geschwind and Flint, 2015; Smoller et al., 2019) Using 
a range of bioinformatic and functional genomic analyses, we find that loci with 
pleiotropic effects are distinguished by their involvement in early neurodevelopment and 
increased expression beginning in the second trimester of fetal development and 
persisting throughout adulthood.  
 
Taken together, the analyses presented here suggest that genetic influences on 
psychiatric disorders comprise at least two general classes of loci. The first comprises a 
set of genes that confer relatively broad liability to psychiatric disorders by acting on 
early neurodevelopment and the establishment of brain circuitry. These pleiotropic 
genes begin to come online by the second trimester of fetal development and exhibit 
differentially high expression thereafter. The expression and differentiation of this 
generalized genetic risk into discrete psychiatric syndromes (e.g., ASD, BIP, AN) may 
then involve direct and/or interactive effects of additional sets of common and rare loci 
and environmental factors, possibly mediated by epigenetic effects, that shape 
phenotypic expression via effects on brain structure/function and behavior. Further 
research will be needed to clarify the nature of such effects.   
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Our results should be interpreted in light of several limitations. First, while our dataset is 
the largest genome-wide cross-disorder analysis to date, data available for individual 
disorders varied substantially—from a minimum of 9,725 cases and controls for OCD to 
461,134 cases and controls for MD. This imbalance of sample size may have limited our 
power to detect pleiotropic effects on underrepresented disorders. The future availability 
of larger samples will improve power for detection of cross-disorder effects. Second, it is 
possible that comorbidity among disorders contributed to apparent pleiotropy; we found, 
however, that fewer than 2% of cases overlapped between disorder datasets (excluding 
23andMe data) and we adjusted for sample overlap in meta-analysis. Third, the method 
we applied to detect cross-phenotype association, which combines an all-subsets fixed-
effects GWAS meta-analysis with a Bayesian method for evaluating the best-fit 
configuration of genotype-phenotype associations, is one of several approaches 
(Solovieff et al., 2013). However, we have previously shown that this method 
outperforms a range of alternatives for detecting pleiotropy under various settings (Zhu 
et al., 2018). Fourth, our designation of loci as pleiotropic vs. non-pleiotropic loci refers 
only to their observed effects on the eight target brain disorders. Thus, some of the 
“non-pleiotropic” loci may have additional effects on psychiatric phenotypes that were 
not included in our meta-analysis and/or on non-psychiatric phenotypes. Fifth, our 
functional genomic analyses were constrained by the limitations of existing resources 
(e.g. spatiotemporal gene expression data resources). Our work underscores the need 
for more comprehensive functional data including single cell transcriptomic and 
epigenomic profiles across development and brain tissues. Lastly, we included only 
individuals of European ancestry to avoid potential confounding due to ancestral 
heterogeneity across distinct disorder studies. Similar efforts are needed to examine 
these questions in other populations. 
  
In sum, in a large-scale cross-disorder genome-wide meta-analysis, we identified three 
genetic factors underlying the genetic basis of eight psychiatric disorders. We also 
identified 109 genomic loci with pleiotropic effects, of which 33 have not previously been 
associated with any of the individual disorders. In addition, we identified 11 loci with 
opposing directional effects on two or more psychiatric disorders. These results 
highlight disparities between our clinically-defined classification of psychiatric disorders 
and underlying biology. Future research is warranted to determine whether more 
genetically-defined influences on cross-diagnostic traits or subtypes of dissect may 
inform a biologically-informed reconceptualization of psychiatric nosology.  Finally, we 
found that genes associated with multiple psychiatric disorders are disproportionately 
associated with biological pathways related to neurodevelopment and exhibit distinctive 
gene expression patterns, with enhanced expression beginning in the second prenatal 
trimester and persistently elevated expression relative to less pleiotropic genes. 
Therapeutic modulation of pleiotropic gene products could have broad-spectrum effects 
on psychopathology.     
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Figure Titles and Legends  
 
Figure 1. Genetic relationships between eight psychiatric disorders. A) SNP-based 
genetic correlations (rg) were estimated between eight neuropsychiatric disorders using 
LDSC. The size of the circles scales with the significance of the p-values. The darker 
the color, the larger the magnitude of rg. Star sign (*) indicates statistical significance 
after Bonferroni correction. (B) SNP-based genetic correlations between eight disorders 
were depicted using an in-directed graph to reveal complex genetic relationships. Only 
significant genetic correlations after Bonferroni correction in (A) were displayed. Each 
node represents a disorder, with edges indicating the strength of the pairwise 
correlations. The width of the edges increases, while the length decreases, with the 
absolute values of rg.  (C) Based on the results of an exploratory factor analysis of the 
genetic correlation matrix produced from multivariable LD-score regression, a 
confirmatory factor model with three correlated genetic factors was specified using 
Genomic SEM and estimated with the weighted least squares algorithm. In this solution, 
each common genetic factor (i.e., F1g,  F2g, F3g) represents variation in genetic liability 
that is shared across the disorders that load on it. These common factors are specified 
so as to account for the genetic covariation among the psychiatric disorders. For 
example, F1g represents shared genetic liability among disorders characterized by 
compulsive behaviors (AN, OCD and TS). One-headed arrows connecting the common 
genetic factors to the individual disorders represent standardized loadings, which can 
be interpreted as coefficients from a regression of the true genetic liability for the 
disorder on the common factor. Two-headed arrows connecting the three factors to one 
another represent their correlations. Two-headed arrows connecting the genetic 
components of the individual psychiatric disorders to themselves represent residual 
genetic variances and correspond to the proportion of heritable variation in liability to 
each individual psychiatric disorder that is unexplained by the three factors. 
Standardized parameters are depicted with their standard errors in parentheses. Paths 
labeled 1 with no standard errors reported are fixed parameters, which are used for 
scaling. 
 
Figure 2. Results of cross-disorder meta-analysis and candidate gene mapping. 
(A) Quantile-quantile (QQ) plot displaying the observed meta-analysis statistics vs. the 
expected statistics under the null model of no associations in the -log10(p-value) scale. 
Although a marked departure is notable between the two statistics, the estimated 
lambda1000 and the estimated LD Score regression intercept indicate that the observed 
inflation is mainly due to polygenic signals rather than major confounding factors 
including population stratification. (B) Gene prioritization strategies for significantly 
associated loci. Candidate genes were mapped on each locus if the index SNP and 
credible SNPs reside within a protein-coding gene, are eQTL markers of the gene in the 
brain tissue, or interact with promoter regions of the gene based on brain Hi-C data. (C) 
Manhattan plot displaying the cross-disorder meta-analysis results highlighting 
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candidate genes mapped to top pleiotropic regions. When multiple genes were mapped 
to the same locus, genes encompassing the index SNP or genes with the largest 
number of evidences were displayed for clarity. Candidate genes that have not 
previously implicated in individual disorder GWAS are marked with an asterisk.    
 
Figure 3. Profile of disorder associations for illustrative pleiotropic loci: (A) 
rs8084351 on 18q21.2; (B) rs7193263 on 16p13.3; (C) rs117956829 on 11q14.3; and 
(D) rs10265001 on 7q34. For each locus, disorder-specific effects of the index SNP are 
shown using ForestPMPlot. The first panel is the forest plot, displaying disorder-specific 
association p-value, log odds ratios (ORs), and standard errors of the SNP. The meta-
analysis p-value and the corresponding summary statistic are displayed on the top and 
the bottom of the forest plot, respectively. The second panel is the PM-plot in which X-
axis represents the m-value, the posterior probability that the effect eixsts in each 
disorder, and the Y-axis represents the disorder-specific association p-value as -log10(p-
value). Disorders are depicted as a dot whose size represents the sample size of 
individual GWAS. Disorders with estimated m-values of at least 0.9 are colored in red, 
while those with m-values less than 0.9 are marked in green. 
 
Figure 4. Eleven loci with opposite directional effects. The radius of each wedge 
corresponds to the absolute values of the Z-scores (log(Odds ratios)/S.E) obtained from 
association tests of the SNP for eight disorders. The color indicates whether the 
examined SNP carries risk (red) or protective effects (green) for each disorder. The 
dotted line around the center indicates statistically significant SNP effects that account 
for multiple testing of 206 SNPs the q-value of 0.001.     
 
Figure 5. Results of functional genomics data analysis for pleiotropic vs. 
disorder-specific loci. (A) GTEX tissue-specific enrichment results for 146 risk loci 
associated with at least one of eight neuropsychiatric disorders. GTEX tissues were 
classified as 9 distinct categories, of which the brain tissues were colored in blue. The 
dotted red line indicates a statistically significant p-value after conducting Bonferroni 
correction for multiple testing. Psychiatric disorder-associated loci show significant 
enrichment in genes expressed in pituitary and all brain tissues except nerve_tibal. (B) 
Brain developmental expression trajectory displayed for the three groups of genes 
based on (Kang et al., 2011) The 146 genome-wide significant loci from the cross-
disorder meta analysis were clustered into three groups based on predicted disorder-
specific associations: (1) no-pleiotopy; (2) pleiotropy=2; and (3) pleiotropy>2. The “no-
pleiotropy” group included 37 loci that showed a single-disorder-specific association, 
while the “pleiotropy=2” and “pleiotropy>2” groups included 60 and 49 loci that were 
associated with two and more than two disorders, respectively. (C) In the adult cortex, 
genes mapped to pleiotropic loci were enriched for frontal cortex specific genes, while 
genes mapped to non-pleiotropic loci are enriched for occipical cortex specific genes. 
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(D) Genes mapped to 146 risk loci show higher expression values in neurons and 




Table Titles and Legends 
 
Table 1. Summary of eight neuropsychiatric disorder datasets 











ADHD 19,099 34,194 53,293 9 0.05 0.222 (0.014) Demontis et al. 2019 
AN 3,495 10,983 14,478 0 0.01 0.195 (0.029) Duncan et al. 2017 
ASD 18,381 27,969 46,350 5 0.01 0.113 (0.010) Grove et al. 2019 
BIP 20,352 31,358 51,710 17 0.01 0.182 (0.011) Stahl et al. 2019 
MD 130,664 330,470 461,134 44 0.15 0.085 (0.004) Wray et al. 2018 
OCD 2,688 7,037 9,725 0 0.025 0.280 (0.041) IOCDF-GC and OCGAS 2018 
SCZ 33,640 43,456 77,096 108 0.01 0.222 (0.012) Schizophrenia Working Group of PGC. 2014 
TS 4,645 8,695 13,340 0 0.008 0.200 (0.026) Yu et al. 2019 
Total 232,964 494,162 727,126     
 
The number of cases and controls used in the meta-analysis of the present study. The numbers 
may differ from those reported in the original publications because our study included only 
European ancestry subjects to avoid potential confounding due to ancestral heterogeneity 
across distinct disorder studies. SNP heritability was estimated from the GWAS summary 





Table 2. Summary of 23 loci with the broadest cross-disorder association 
SNP CHR BP Candidate Gene (evidence) ADHD ANO ASD BIP MD OCD SCZ TS m 
rs8084351 18 50726559 DCC(g,q) 0.961 0.905 0.97 0.965 1 0.951 1 0.984 8 
rs7193263 16 6315880 RBFOX1(g) 0.924 0.802 0.984 0.995 1 0.902 0.901 0.932 7 
rs12658451 5 103904037 - 0.963 0.165 0.999 0.972 1 0.574 1 0.963 6 
rs34215985 4 42047778 SLC30A9(g,q) DCAF4L1(tss) 0.908 0.926 0.992 0.843 1 0.88 0.929 0.913 6 
rs61867293 10 106563924 SORCS3(g,ha,hf) 0.987 0.954 0.992 0.985 1 0.854 1 0.886 6 
rs9360557 6 73132745 KCNQ5(ha,hf) KCNQ5-IT1(hf) 0.905 0.938 0.976 0.984 0.993 0.897 1 0.892 6 
rs10149470 14 104017953 APOPT1(fg) C14orf2(ha) 0.844 0.833 0.998 0.979 1 0.868 0.997 0.97 5 
rs11570190 11 57560452 CTNND1(g,tss) OR5AK2(q) 0.927 0.79 0.97 0.58 1 0.916 1 0.832 5 
rs117956829 11 89339666 GRM5(hf) NOX4(ha,hf) 0.723 0.929 0.972 0.906 1 0.66 0.997 0.789 5 
rs1484144 4 80217597 NAA11(fg) 0.97 0.884 0.973 0.98 1 0.84 0.998 0.85 5 
rs6969410 7 110069015 - 0.836 0.827 0.987 0.93 0.999 0.917 1 0.729 5 
rs7531118 1 72837239 NEGR1(hf) 0.74 0.949 0.963 0.785 1 0.858 0.973 0.921 5 
rs9787523 10 106460460 SORCS3(g) 0.944 0.855 0.972 0.877 1 0.853 0.999 0.963 5 
rs10265001 7 140665521 MRPS33(tss) KDM7A(ha) 0.716 0.772 0.986 0.999 0.783 0.921 0.988 0.692 4 
rs11688767 2 57988194 BCL11A(h) LINC01122(ha,hf) 0.845 0.899 0.929 0.983 1 0.849 1 0.698 4 
rs12129573 1 73768366 - 0.929 0.835 0.894 0.948 1 0.85 1 0.539 4 
rs1518367 2 198807015 PLCL1(g) SF3B1(ha,q) 0.897 0.783 0.913 0.991 1 0.674 1 0.865 4 
rs2332700 14 72417326 RGS6(g) 0.755 0.884 0.951 0.948 0.999 0.885 1 0.817 4 
rs5758265 22 41617897 CHADL(g,ha,hf)  L3MBTL2(g,ha) 0.735 0.885 0.89 0.885 1 0.913 1 0.978 4 
rs6125656 20 48090779 KCNB1(g) SPATA2(hf)  0.768 0.885 0.986 0.995 0.985 0.731 0.999 0.707 4 
rs7405404 16 13749859 - 0.763 0.765 0.99 0.939 1 0.726 1 0.562 4 
rs78337797 12 23987925 SOX5(g) 0.849 0.797 0.97 0.954 1 0.831 0.996 0.885 4 
rs79879286 7 24826589 DFNA5(fg,tss) MPP6(fg) 0.865 0.854 0.966 0.999 1 0.734 0.999 0.798 4 
SNP ID, location, prioritized candidate gene, disorder-specific m-values for 23 most pleiotropic loci. 
The number of disorders with high confidence association (m-values ≥0.9) is shown in the last 
column. Evidence for candidate gene mapping include: g (gene containing index SNP); fg (credible 
SNP gene);  q (brain cis-eQTLs); h (hi-C interacting gene based on FUMA); hf (hi-C-based 
interaction between associated SNP and target gene in the fetal brain from Won et al. 2016); ha (hi-
C-based interaction in the adult brain from Wang et al. 2018); and tss (transcription start sites). Loci 
were highlighted if the LD-independent regions do not overlap with genome-wide significant 
associations previously identified in the GWAS of individual disorders. At most two candidate genes 





Supplementary Figure Titles and Legends  
Note: Related Figures are grouped into “Supplementary Datafiles” 
 
Figure S1. Statistical power and number of cross-disorder associations (Related 
to Table 2 and Table S3.1). Power to detect associations across pairs of disorders was 
plotted with the number of cross-disorder associations identified in the current meta-
analysis. For each pair of disorders, power was estimated using the number of cases 
and heritability for each disorder, as well as the genetic correlation between the 
disorders. In general, as power increased, so did the number of identified SNPs. 
 
Figure S2. Cross-disorder GWAS SNPs in the DCC locus colocalize with eQTLs 
for DCC (Related to Table 2, Table S4.2, and Figure 3). Dark blue dots refer to SNPs 
that overlap between brain eQTLs and GWAS plots. LD region for the GWAS locus and 
TAD boundaries are depicted. 
 
Figure S3. Gene expression of top loci across development (Related to Figure 3). 
Gene expression trajectories from a transcriptome atlas of post-mortem brain tissue 
across development are plotted for four top loci, DCC, RBFOX1, NOX4 and BRAF in six 
different brain tissue types. AMY = amygdala; MD = mediodorsal nucleus of the 
thalamus; CBC = cerebellar cortex; NCX = neocortex; HIP = hippocampus; STR = 
striatum.  
 
Figure S4. Gene expression in the brain for pleiotropic and non-pleiotropic loci 
(Related to Figure 5). Average normalized gene expression in fetal and adult post-
mortem brain tissue for pleiotropic (109) and non-pleiotropic (37) loci were plotted. 
Disorder-specific and pleiotropic risk loci showed a similar level of gene expression in 




STAR* METHODS  
 
LEAD CONTACT AND MATERIALS AVAILABILITY 
 
Any inquiries about analytical results or other information should be directed to Lead 
Contact, Jordan W. Smoller (jsmoller@mgh.harvard.edu).  
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Genotyped sample description 
Genotype data from eight studies of genetic associations with psychiatric disorders 
conducted by the Psychiatric Genomics Consortium were included in this report. A 
summary of each study is provided below, however, detailed sample descriptions are 
available in the primary publication. The lead PI of every cohort included across studies 
certified that their protocol was approved by their local Ethical Committee. 
Supplementary Table S1 lists for each disorder the number of cases and controls, the 
number of loci identified in the single disorder genome-wide association study, and 
SNP-based heritability. 
 
Schizophrenia | Ripke et al., 2014 
108 loci were identified as associated with schizophrenia in a case-control meta-
analysis including 150,064 individuals. For the current study, the 46 case-control 
cohorts of European ancestry were retained, totaling 33,640 cases and 43,546 controls. 
Cases were defined as individuals diagnosed with schizophrenia or schizoaffective 
disorder, which was determined by research-based assessment or clinician diagnosis 
depending on the sample.  
 
Bipolar disorder | Stahl et al., 2019 
Thirty-two case-control cohorts from Europe, North America, and Australia 
including 20,352 cases and 31,358 controls of European ancestry were meta-analyzed 
to identify 30 loci associated with bipolar disorder. Cases met criteria for lifetime 
diagnosis of bipolar disorder as defined by DSM-IV, ICD-9, or ICD-10, which was 
established using interview-based structured assessment, clinician-administered 
checklists, or review of medical records. All subjects in the meta-analysis were included 
in the current study. 
 
Major depression | Wray et al., 2018 
Seven case-control cohorts were combined to identify 44 loci associated with 
major depression. The first cohort included 29 case-control samples of European 
descent where lifetime diagnosis of major depressive disorder was ascertained using 
structured clinical interviews (DSM-V, ICD-9, ICD-10), clinician-administered checklists, 
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or review of medical records. Six additional cohorts of European ancestry, including the 
Hyde et al study (23andMe, Inc), determined case status using other methods including 
national or hospital treatment registers, self-reported symptoms or treatment by a 
medical professional, or direct interviews. Analyses comparing the original cohort with 
the additional ones indicated strong correlation of common genetic variants and little 
evidence of heterogeneity. 130,664 cases and 330,470 controls from these cohorts 
were included in the current analyses.  
 
Attention deficit hyperactive disorder | Demontis et al., 2019 
Twelve cohorts of European, North American, and Chinese descent were 
aggregated in a meta-analysis of attention deficit and hyperactive disorder, revealing 12 
associated loci. For the first cohort, cases were ascertained using the Danish 
Psychiatric Central Research Registrar and diagnoses were confirmed by psychiatrists 
according to ICD-10. The remaining studies included four parent-offspring trio cohorts 
and seven case-control cohorts. Cases were recruited from clinics, hospitals or through 
medical registries and diagnosed using research-based assessments administered by 
clinicians or trained staff. 19,099 cases and 34,194 controls of European ancestry were 
included in the current study.   
 
Autism spectrum disorder | Grove et al., 2019 
Five family-based cohorts of European descent and a population-based case-
control sample from Denmark were combined to discover five loci associated with 
autism spectrum disorder. In each family study, diagnosis was confirmed for all affected 
individuals using standard research tools and expert clinical consensus diagnosis. In the 
population-based cohort, cases were identified using the Danish Psychiatric Central 
Research Register and were diagnosed with ASD before 2013 by a psychiatrist 
according to ICD-10. All subjects in this sample were included here (18,381 cases; 
27,969 controls). 
 
Obsessive compulsive disorder | IOCDF-GC and OCGAS, 2018 
Individuals of European descent from two cohorts were combined in this meta-
analysis including 2,688 cases and 7,037 controls; no loci reached genome-wide 
significance. Case diagnoses were established using DSM-IV criteria and controls were 
unscreened. All cases and controls were included in the current analyses.  
 
Anorexia nervosa | Duncan et al., 2017 
3,495 cases from two consortia and 10,982 matched controls from the 
Psychiatric Genomics Consortium, all of European descent, were meta-analyzed to 
identify one locus associated with anorexia nervosa. Cases met criteria as defined by 
DSM-IV for lifetime diagnosis of anorexia nervosa (restricting or binge-purging subtype), 
bulimia nervosa, or anorexia nervosa – not otherwise specified, anorexia nervosa 
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subtype. All individuals included in the primary study were included in the current 
analyses.  
 
Tourette Syndrome | Yu et al., 2019 
Three case-control cohorts and one family-based cohort from Europe and North 
America including 4,819 cases and 9,488 controls of European ancestry were meta-
analyzed to identify one locus associated with Tourette Syndrome. All cases met DSM-
IV-TR or DSM-5 criteria for Tourette syndrome, except for 12 cases who met DSM-5 
criteria for chronic motor or vocal tic disorder. All cases were recruited by Tourette 
syndrome specialty clinics or by email/online recruitment combined with validated, web-
based phenotypic assessments.  
 
Genotype quality control, imputation, and association analysis 
All primary studies used the standardized PGC ricopili pipeline for quality control, 
imputation and association testing. Briefly, for each dataset, poor quality SNPs and 
samples missing >5% SNPs were removed. Next, pre-phasing and imputation were 
implemented using IMPUTE2 (Howie et al., 2011) and the 1000 Genomes reference 
panel. High quality SNPs (INFO > 0.8) with low missingness (<1%) were retained. A 
subset of these markers (MAF > 0.05; pruned for linkage disequilibrium, r2 > 0.02) were 
used to assess relatedness and population stratification. Only one of any pair of related 
individuals was retained. Each imputed dataset was tested for association with the 
disease outcome of interest using an additive logistic regression model in PLINK 
(Purcell et al., 2007) with age, sex, and 10 principal components included as covariates. 
Finally, a meta-analysis within each disease category was done using an inverse-
weighted fixed effects model. After extracting SNPs commonly exist in all eight disorder 
studies, we removed 3,591 SNPs whose alleles were incompatible. For palindromic 
SNPs, we compared allele frequencies between eight studies to check strand 
ambiguity. 50 SNPs with frequency difference greater than 15% from the 1KG reference 
was excluded. As a result, 6,786,993 autosomal SNPs remained for further analysis. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Genome-wide SNP-heritability estimation 
For each of the eight GWAS disorders, LD Score regression was performed on the 
summary statistics of individual disease using LDSC to estimate SNP-based heritability 
in the liability scale and genetic correlation between pairs of disorders (Bulik-Sullivan et 
al., 2015b). LD scores and weights for European populations were downloaded from the 
LDSC website (http://www.broadinstitute.org/~bulik/eur_ldscores/). SNPs were removed 
if the minor allele frequency is smaller than 5% or an imputation quality score is less 
than 0.9; MHC region was excluded from the analysis. For single-trait LDSC, the slope 
of the regression estimates the SNP-based heritability, and the intercept greater than 
one captures the inflation in the summary statistics due to population stratification or 
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other confounding factors. We confirmed that the heritability Z-scores (i.e., a measure of 
the polygenic signals) are greater than four, and the LDSC intercepts are approximately 
one and less than . suggesting that the increase in mean χ2 statistics is due to 
polygenicity and not due to stratification. 
 
Factor analysis and genomic SEM 
Genomic SEM’s Multivariable LD score regression method (Grotzinger et al., 2019) was 
first used to estimate the genetic covariance matrix (S) and sampling covariance matrix 
(V) for the eight psychiatric traits. Quality control for this step included removing SNPs 
with an MAF < 1%, information scores < .9, SNPs from the MHC region, and filtering 
SNPs to HapMap3. All SNP effects were standardized using the sumstats function in 
Genomic SEM. To examine genome-wide factor structure, models using only the 
genetic covariance and sampling covariance matrix were fit. Genomic SEM provides 
indices of model fit—standardized root mean square residual (SRMR), model 2, Akaike 
Information Criteria (AIC), and Comparative Fit Index (CFI)—that can be used to 
determine how well the proposed model captures the observed data. Model fit for the 
common factor model in which the loadings were freely estimated was only fair, (2 (20) = 
313.94, AIC = 345.9, CFI = .786, SRMR = .149), suggesting that there were nuances in 
the genetic architecture not fully captured by a single cross-trait index of genetic risk. An 
exploratory factor analysis (EFA) of the S matrix with three-factors using the promax 
rotation in the R package factanal was then used to guide construction of a follow-up 
model (Table S2.2). A follow-up confirmatory model with three correlated factors was 
specified in Genomic SEM based on the EFA parameter estimates (positive 
standardized loadings > .2 were retained; Figure 2b). This model provided good fit to 
the data (2 (15) = 85.35, AIC = 127.36, CFI = .945, SRMR = .079). Results indicated 
there was a moderate genetic correlation between the compulsive and mood/psychotic 
disorders factors (rg = .43, SE = .08), a smaller genetic correlation between the 
mood/psychotic and early onset factors (rg = .25, SE = .05), and next to no correlation 
between the compulsive and early onset factors (rg = < .01, SE = .07). A model that 
included additional negative cross-loadings provided similar fit to the data and highly 
similar correlations across the genetic factors. Given this consistency in results, the 
correlated factors model with SNP effects only included positive loadings. 
 
Summary-data-based meta-analysis 
To identify genomic loci shared across multiple neuropsychiatric disorders, we 
performed primary meta-analysis using the subset-based fixed-effects method ASSET 
(Bhattacharjee et al., 2012). Standard meta-analysis pools the effect of a given SNP 
across K studies, weighting the effects by the size of the study. By exhaustive 
investigation of all subset-based effects, the maximum SNP effect was identified as: 




where the absolute value of the subset-specific effect [Z(S)] over class S of all possible 
subsets of K studies is highest. The numbers of shared subjects across eight disorder 
studies were identified using the PGC checksum algorithm, and Zmeta was standardized 
so that covariance between the statistics can be accounted for as previously described 
(Bhattacharjee et al., 2012; Lin and Sullivan, 2009).  Tail probabilities for the distribution 
of the maximum, adjusting for multiple testing of all combination of subsets, were then 
estimated with the discrete local maxima method, which uses the correlation structure of 
test statistics across subsets. Based on the derived p-value, standard deviation of the 
SNP effect was adjusted to reflect the multiple-testing correction. Even when correcting 
for all subset tests (2K-1), simulations suggest there is a substantial gain in power using 
this test relative to traditional meta-analysis (Bhattacharjee et al., 2012. Standardized 
genomic inflation factor (λ1000) for the meta-analysis result was close to one. LDSC 
intercept was substantially less than λGC (0.79 vs 1.55), suggesting that the increase in 
mean χ2 statistics in the cross-disorder meta-analysis is mainly due to polygenicity and 
not due to stratification or other confounding biases. 
 
Once SNPs with genome-wide significant association were identified, we identified LD-
independent genomic regions using PLINK clumping (--clump-r2=0.4, --clump-kb=500, -
-clump-p1=5e-08, --clump-p2=5e-02). Genomic regions were merged if they physically 
overlap using bedtools. Due to extensive LD, the MHC region was considered as one 
region (chr6:25-35Mb). To detect secondary signals independent of index SNP in each 
of the candidate cross-disorder loci, conditional analysis was performed with GCTA-
COJO (Yang et al., 2012) using meta-analysis summary statistics from ASSET. 1KG 
EUR population was used as the reference panel for estimating LD. For each genomic 
region harboring a cross-disorder signal, we tested the presence of any additional 
associated SNPs using a stepwise procedure (--cojo-slct), conditioning on the primary 
significant SNP for model initiation. A conditional p-value for each variant was reported, 
adjusted for genomic control and collinearity. In each region, additional SNPs were 
selected as a distinct association signal if having a conditional p-value < 1e-06. 
 
Disease-association modeling 
We estimated posterior probabilities for each of the top loci identified from the meta-
analysis to quantify disorder-specific effects (Han and Eskin, 2012). This estimation, 
known as the m-value, relies on two assumptions, 1) effects are either present or 
absent in studies, and 2) if they are present, they are similarly sized across studies. 
Assume Xi is the observed effect size of study i, and Ti is a random variable with value 1 
if study i has an effect and 0 if not, then the m-value can be estimated using Bayes’ 
theorem: 
𝑚𝑚𝑖𝑖 = 𝑃𝑃(𝑇𝑇𝑖𝑖 = 1|𝑋𝑋) =
𝑃𝑃(𝑋𝑋|𝑇𝑇𝑖𝑖 = 1)𝑃𝑃(𝑇𝑇𝑖𝑖 = 1)





which can then be used to predict whether an effect exists in a given study (>.9) or not 
(<.1) under the binary effects assumption.  
 
Examination of the Impact of Sample Size Imbalance on Genetic Correlations and 
Genomic SEM Results 
We conducted several analyses to examine whether differences in sample size among 
the 8 disorders influenced the pattern of cross-disorder genomic relationships we 
observed. First, we note that while sample size will affect the precision of a genetic 
correlation estimate (ie standard error) it should not affect the magnitude of the estimate 
itself (Bulik-Sullivan et al. 2015).  As shown in Data S1.2, there is no substantial 
relationship between the estimated genetic correlations and the effective sample sizes 
of the corresponding disorder pairs (p-value for the slope = 0.055 ). The slightly positive 
linear relationship appears to be driven by MD and its genetic correlation with the other 
four major psychiatric disorders (SCZ, BIP, ASD, ADHD), however, these estimates are 
generally consistent with previously reported ones when sample sizes are much smaller 
(except for ASD) (Brainstorm et al., 2018) (Cross-Disorder Group of the Psychiatric 
Genomics et al., 2013) (Data S1.3).  Furthermore, the largest among all pairwise 
comparisons, such as those between SCZ-BIP, AN-OCD, and ADHD-AN, do not scale 
with sample size. 
Next, we investigated the impact of variable sample sizes on the Genomic SEM 
analysis results by re-running Genomic SEM analysis using a Maximum Likelihood (ML) 
estimator that does not take into account the differing precisions of the genetic 
covariance estimates (resulting from, for example, uneven sample sizes across traits) 
when optimizing parameters. As shown in Data S1.4, the results were consistent with 
those from the primary analysis reported in the main text that is based on a Weighted 
Least Squares (WLS) estimator, which does take into account the differing precisions of 
the genetic covariance estimates. Specifically, the nontrivial standardized factor 
loadings of MD on two of the three factors is evident in both the WLS and ML solutions 
and is therefore unlikely to be an artifact of its large N. Note that, in both the WLS and 
the ML solution, the standard errors are smaller for the loadings involving the better-
powered GWAS phenotypes, as we would expect.     
 
To further evaluate whether sample size imbalance across the eight disorders biased 
the number of pleiotropic signals we observed, we conducted simulation studies of UK 
Biobank data.  In particular, we examine whether the number of pleiotropic loci we 
identified exceeds chance expectation given the sample size and genetic correlations 
among the eight disorders. We used the full release of 488,377 UK Biobank (UKBB; 
(Sudlow et al., 2015)) individual data, imputed with the Haplotype Reference 
Consortium (HRC), UK 10K, and 1000 Genomes reference panels (under the 
application number 31063). Data was QC’ed as described in the Neale Lab UK 
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BIOBANK GWAS webpage (http://www.nealelab.is/uk-biobank/), including 361,194 
unrelated individuals of Caucasian ancestry and 13.7 million genetic variants (MAF > 
0.0001, INFO > 0.8). For the purpose of the simulation, we removed individuals who 
were in the UKBB interim release to avoid sample overlap with the MD GWAS where 
these subjects were included (Wray et al., 2018) and restricted the analysis to variants 
present in both the current study (PGC-CDG2) and the UKBB datasets, resulting in 
6,691,733 SNPs. 
 
Because SCZ and MD accounted for the majority of the total sample size in our study 
as well as the two most statistically powerful studies (estimated by calculating their 
effective sample size and multiplying that by heritability), we generated simulated 
datasets similar in size and heritability, as well as cross-correlation to the other 
datasets, for each of the six smaller studies (BIP, ADHD, ASD, TS, ANO, and OCD); In 
brief, simulated genetic data was created from the post-QC UKBB imputed data for 
each of the six disorders by randomly selecting subjects without any overlap given their 
original sample sizes. In each simulation replicate, we then simulated quantitative 
phenotypes (Y = ) given true effect sizes, the standardized genotype matrix X, and a 
non-genetic error term. The true effect sizes of each SNP were drawn from a 
multivariate normal distribution , where M is the total number of SNPs in the genome, μ 
is a zero vector of length 6, and ∑ is the covariance matrix that accounts for the genetic 
correlations (rg) among the six disorders (with disease-specific SNP-heritabilities on the 
diagonal and hihjrg,ij on the off-diagonals). Individual phenotypes were then generated 
by calculating the sum of betas weighted by the standardized allele dosages (mean 0 
and variance 1) with the --score variance-standardize option in PLINK2 v2.00a2LM 
(Chang et al., 2015) and a noise term drawn from N(0,) for each disorder. Case-control 
phenotypes were generated by sorting Y in descending order and assigning the top fcase 
to be cases, where fcase corresponds to the fraction of cases of each disorder in the 
original GWAS. Association statistics were estimated using logistic regression, 
assuming an additive effect of alleles. We then matched the reference and the alternate 
alleles in UKBB to those in the current study and reversed the sign of the effect sizes 
when necessary. We then performed meta-analysis using ASSET (Bhattacharjee et al., 
2012) and estimated m-values as was done in the original analysis. Finally, we 
compared the distribution of the number of pleiotropic loci across the 100 simulation 
replicates against the observed value in the actual study. For this analysis, we focused 
on chromosome 1 where the largest number of cross-disorder associations were 
identified in the actual analysis. Data S1.5 displays the distribution of the number of 
cross-disorder loci identified in meta-analysis of chromosome 1 across 100 simulation 
replicates. We compared this to the number of pleiotropic loci found in our meta-
analysis compared to those seen in the simulations, given the sample size and genetic 
correlations among the eight disorders to determine whether the observed number of 
pleiotropic loci exceeds chance expectation.   
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Functional annotation and gene-mapping of genome-wide significant variants  
For the 146 genome-wide significant variants, gene mapping and functional annotation 
was conducted using various resources, including SNPNexus (Dayem et al., 2018) and 
FUMA (Watanabe et al., 2017). Nearest genes and functional consequence of each 
SNP on gene functions were annotated based on ANNOVAR (Wang et al., 2010). 
Combined Annotation Dependent Depletion (CADD) score (Kircher, 2014) indexes the 
deleteriousness of variants computed based on 67 annotation resources. SNPs with the 
CADD score higher than 12 were considered to confer deleterious effects. The 
RegulomeDB (Boyle, 2012) provides a categorical score that describes how likely a 
SNP is likely to play a regulatory role based on the integration of high-throughput 
datasets. The RDB score of 1a suggests the strongest evidence, while the score 7 
represents the least support for a regulatory potential. The minChrState and the 
commonChrState represent the minimum and the most common15-core chromatin state 
across 127 tissue/cell type predicted by ChrHMM. The chromatin state of less than 8 
suggests an open chromatin state. eQTL mapping provides significant cis-SNP-gene 
pairs (up to 1Mb apart) in brain tissue types from GTEx and BRAINEAC.  
 
For chromatin interaction mapping, we first refined the localization of potential causal 
variants for top 146 lead SNPs using FINEMAP (Benner et al., 2016). For each region, 
we considered only SNPs located in the LD region with the lead SNP (r2 > 0.6). We then 
applied the method to calculate the posterior probability of being causal for each of the 
remaining SNPs. A 95% credible set of SNPs for each region was constructed by 
ordering the posterior probability from largest to smallest and selecting in the 
corresponding SNPs up to a cumulative probability of 95%. Credible SNPs were then 
grouped into those that are located within the promoter or exons and those that are non-
coding/intronic. Promoter/exonal SNPs were directly assigned to their target genes 
using positional mapping, while non-coding/intronic SNPs were assigned to their target 
genes based on long range interactions (Hi-C) or expression quantitative trait loci 
(eQTLs). Two Hi-C datasets originated from the human brain (fetal brain Hi-C (Won et 
al., 2016) and adult brain Hi-C (Wang et al., 2018)) were used to map credible SNPs to 
remotely interacting genes as previously described (Wang et al., 2018). A colocalization 
analysis with the recent eQTL dataset from adult prefrontal cortices (PFC) was also 
used to map 146 GWS loci into their target genes (Wang et al., 2018). In the end, we 
obtained two sets of candidate genes, one from fetal brain (positional mapping, fetal 
brain Hi-C), the other from adult brain (positional mapping, adult brain Hi-C, adult brain 
eQTLs).     
 
GTEx gene expression enrichment analysis 
MAGMA gene-property analysis (de Leeuw et al., 2015) was performed using gene 
expression data from 83 tissues based on GTEx RNA-seq data (v7). Expression values 
(RPKM) were log2 transformed with pseudo-count one after winsorization at 50, and 
average expression values were taken per tissue. Analysis was performed separately 
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for 30 general tissue types and 53 specific tissue types, and Bonferroni-based multiple 
testing correction was done for the examined tissue types.  
 
Pathway analysis using Gene Ontology 
We used FUMA (Watanabe et al., 2017) to map SNPs to genes and then test for 
enrichment of specific Gene Ontology functions and pathways among genome-wide 
significant pleiotropic and disorder-specific SNPs separately. Hypergeometric tests 
identify any statistical over-representation of genes from the input list (mapped from 
SNPs) in predefined MSigDB Gene Ontology gene sets which describe biological 
processes, molecular functions, and cellular components. Multiple test correction was 
applied by category. 
 
Enrichment analysis using brain developmental, regional, and cell-type-specific 
data  
Developmental expression trajectories for candidate genes were plotted using a 
published transcriptome atlas constructed from post-mortem brain data (Kang et al. 
2011). As this dataset contains expression values from multiple brain regions, we 
selected transcriptomic profiles of cerebral cortex with developmental epochs that span 
prenatal (6-37 post-conception weeks, PCW) and postnatal (4 months-42 years) 
periods. Expression values were log-transformed and centered to the mean expression 
level for each sample using a scale(center=T, scale=F)+1 function in R. This 
normalization method has been frequently used in other papers to plot developmental 
expression trajectories (e.g. (Grove et al., 2019b; Li et al., 2018; Mah and Won, 2019; 
Satterstrom et al., 2019). Instead of measuring the expression values of individual 
disease associated gene, we measured the average expression values of the entire 
gene set. To do this, disease risk genes were selected for each sample and their 
average centered expression values were calculated and plotted (individual dots in the 
plot denote different samples or individuals, not different genes). It is of note that the 
average expression values each gene set correspond to representative expression 
patterns of the disease risk genes, so individual genes may behave differently.  
We used candidate genes identified in fetal brain and adult brain to plot prenatal and 
postnatal gene expression profiles, respectively.  
 
To obtain genes that show cortical regional enrichment (e.g. frontal cortical enrichment), 
we computed t-statistics for each gene for a specific cortical region (e.g. frontal cortex) 
versus all other cortical regions (e.g. parietal cortex, temporal cortex, and occipital 
cortex, Kang et al. 2011). The top 5% of genes that show heightened expression 
patterns for each cortical region were selected as region-specific genes. These genes 




Single cell expression profiles from the adult brain (Darmanis et al., 2015) were used to 
identify cell-type specificity of candidate genes. Single cell expression values were log-
transformed and centered using the mean expression values. Average centered 
expression values for candidate genes were calculated in each cell. Cells were then 
grouped into cell clusters (neurons, astrocytes, microglia, oligodendrocytes, OPC, and 
endothelial cells), and a relative expression level for a given cell cluster was calculated 
by a scale function in R. 
   
Comparison with other brain-related traits and diseases  
To explore the genome-wide relationship of our cross-disorder phenotype with other 
traits and diseases, we estimated pairwise genetic correlations using LD Hub (Zheng et 
al., 2017). We selected 25 brain-related traits from LD Hub, including phenotypes 
related to smoking behavior, education, personality, neurological disorders, sleeping, 
cognitive function, and brain volume (Table S7.1). Summary statistics for different 
phenotypes were harmonized via the default options provided by LD Hub, and SNPs in 
the MHC regions were removed before the analysis. For each of the selected traits, a 
bivariate LDSC analysis was performed to estimate its genetic correlation with our 
meta-analyzed cross-disorder phenotype. We then applied FDR correction to control for 
multiple testing and identify significant associations. 
 
For GWAS catalog data, FUMA (Watanabe et al., 2017) GENE2FUNC module was 
used to test for enrichment of specific GWAS catalog-associated gene sets for genome-
wide significant pleiotropic risk loci. Hypergeometric tests identified any statistical over-
representation of genes from the input list in predefined GWAS catalog data. Human 
protein-coding genes were used as  background genes. All identified traits with multiple-
testing adjusted P < 0.05 were included as results.  
 
Relationship of Lead SNPs from Meta-analysis to Rare CNVs and Mutations 
Previously Associated with Neurodevelopmental Genomic Disorders 
We conducted additional analyses to determine whether our 146 genome-wide 
significant loci are enriched in CNVs spanning defined genomic disorder (GD) regions 
or damaging mutations previously shown to be associated with neurodevelopmental 
disorders (including autism spectrum disorder, intellectual disability, and developmental 
delay), also known as genomic disorders (GDs). The reference data comprise a curated 
set of 51 GD loci (encompassing 823 protein-coding genes) with multiple reports of 
ASD/ID/DD-associated CNVs (Satterstrom et al., 2019). The GD curation process is 
described in the original publication. Each of our 146 lead SNPs were assigned to its 
candidate genes using various functional genomics datasets including Hi-C data, 
overlap with gene and regulatory elements. We examined all SNPs as well as dividing 
SNPs into groups based on their degree of pleiotropic association and conducted 
permutation testing to assess significant enrichment. Permutation testing was 
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performed by first assigning each lead (sentinel) SNP to the nearest gene, then 
randomly sampling 1,000 new genes from the genome with replacement while matching 
on chromosome and gene length. P-values were derived by comparing the empirically 
observed number of overlaps to the distribution of expected overlaps based on 1,000 
matched permutations (Data S3.1). 
 
We also examined overlap of our 146 genomewide significant loci with genes containing 
damaging de novo (truncating, highly damaging missense and damaging missense) 
mutations among children with ASD (data from (Satterstrom et al., 2019)). In this autism 
dataset, 102 genes had higher frequencies of damaging de novo mutations (DNMs) in 
cases than controls (FDR q < 0.1) (Satterstrom et al., 2019). Each permutation test 
consisted of randomly sampling 1,000 new sets of genes with replacement from the 
genome, where each new set of genes contained the same total number of genes as 
the observed set of candidate genes for each set of loci. Sampling was also performed 
while controlling for per-gene mutation rates and brain expression levels using a 
quantile-based binning approach, as has been described in detail in a recent study 
(Satterstrom, et al., 2019). P-values were derived by comparing the empirically 
observed number of genes present in the list of 102 dominant-acting ASD risk genes to 
the distribution of expected count of dominant-acting ASD risk genes based on 1,000 
matched permutations (Data S3.2). 
Finally, we examined whether genes linked to our SNPs were enriched for DNMs 
associated with ASD using the same reference data set. Each permutation test 
consisted of randomly sampling 1,000 new sets of genes with replacement from the 
genome, where each new set of genes contained the same total number of genes as 
the observed set of candidate genes for each set of loci. Sampling was also performed 
while controlling for per-gene mutation rates and brain expression levels using a 
quantile-based binning approach, as has been described in detail in a recent study 
(Satterstrom, et al., 2019). P-values were derived by comparing the empirically 
observed number of genes present in the list of 102 dominant-acting ASD risk genes to 
the distribution of expected count of dominant-acting ASD risk genes based on 1,000 
matched permutations (Data S3.3). 
DATA AND SOFTWARE AVAILABILITY 
The Psychiatric Genetics Consortium (PGC)’s policy is to make genome-wide summary 
results publicly available. Summary statistics for a combined meta-analysis of eight 
psychiatric disorders without 23andMe data are available on the PGC web site 
(https://www.med.unc.edu/pgc/results-and-downloads).  Results for 10,000 SNPs for 
eight disorders including 23andMe are also available on the PGC web site. The 
summary-level GWAS association statistics for PGC individual disorders are available 
at the website (https://www.med.unc.edu/pgc/results-and-downloads). 
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GWAS summary statistics for the 23andMe cohort (Hyde, 2016) must be obtained 
separately. These can be obtained by individual researchers under an agreement with 
23andMe that protects the privacy of the 23andMe participants. Contact Aaron 
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Supplemental Datafile 1: Additional analysis results to assess the robustness of 
genetic correlation and Genomic SEM study (Related to Figure 1). Data S1.1. 
displays the hierarchical clustering of genetic architecture across eight neuropsychiatric 
disorders. Data S 1.2. summarizes the relationship between the estimated genetic 
correlation and the effective sample sizes for each pair of disorders. Data S1.3. shows 
the relationship between the estimated genetic correlation and the effective sample 
sizes for MD and four other disorders, SCZ, BIP, ADHD, and ASD. Data S1.4. depicts 
the genomic SEM analysis result using a Weighted Least Squares estimator and that 
based on a Maximum Likelihood estimator. Data S1.5. summarizes the distribution of 
the number of cross-disorder loci identified in meta-analysis of chromosome 1 across 
100 simulation replicates.  
Supplementary Datafile 2: P-M plots for 146 LD-independent genome-wide 
significant loci (Related to Figure 3). P-M plot is displayed on the right side for each 
SNP locus. The X-axis on a P-M plot represents M-values estimated for each locus for 
each disorder, while the Y-axis displays the significance of disease-SNP association. 
Disorders displayed in red dots were predicted to have an effect (M-value 0.9), 
disorders in blue were predicted to not have an effect (M-value 0.1), and studies in 
green indicated its effect is uncertain (0.1< M-value < 0.9). The dot size reflects the 
relative sample size of the studies. On the left side, a forest plot displays log odds ratios 
for the effect of the SNP on each disorder and a meta-analyzed effect across disorders. 
As expected, most of the top SNPs (109/146) show pleiotropic effects.  
Supplementary Datafile 3: Analyses of rare CNVs and mutations previously 
associated with neurodevelopmental genomic disorders (Related to STAR 
Methods section “Relationship of Lead SNPs from Meta-analysis to Rare CNVs 
and Mutations Previously Associated with Neurodevelopmental Genomic 
Disorders”) Data S3.1. shows that sentinel SNPs are not overrepresented among 
genomic disorder loci. Data S3.2. and Data S3.3. indicate that genes linked to sentinel 
SNPs are not overrepresented among dominant-acting ASD risk genes and for 





Table S1. Summary of eight neuropsychiatric disorder datasets (Related to Table 
1). Disease-specific cases and controls included in the meta-analysis, number of 
individual GWAS loci, and liability-based SNP heritability estimates are provided. 
Heritability was estimated from available European summary statistics using LD score 
regression. 
 
Table S2. Tables Related to STAR Methods, Figure 1 and Figure S1. Table S2.1. 
displays the genetic correlations estimated by LD score regression, while Table S2.2. 
shows the results from EFA of genetic covariance matrix.  
 
Table S3. Tables Related to Figure 2, 3, and 4. Table S3.1. displays the list of 146 
lead SNPs, and Table S3.2. shows the M-value estimates for quantifying confidence of 
disorder-specific association for all 146 lead SNPs. Table S3.3. summarizes the loci 
with opposite directional effects.  
 
Table S4: Tables Related to Table 2, Table S3.1. Table S4.1. summarizes the 
functional annotation of 146 lead SNPs, while Table S4.2. lists the Brain eQTL and Hi-C 
data annotation based on FUMA database. Table S4.3. lists the GWAS catalog data for 
lead SNPs.   
 
Table S5: Tables Related to Figure 5, Gene Expression Enrichment Analyses. 
Table S5.1. summarizes the GTEx gene enrichment analysis results using MAGMA. 
Table S5.2. and S5.3 show the tissue enrichment analysis for pleiotropic and disorder-
specific risk loci using MAGMA (GTEx v7), respectively.  
 
Table S6: Tables Related to Figure 5. Table S6.1. and S6.2 summarize the Gene 
ontology analysis for pleiotropic and disease-specific risk loci, respectively. Table S6.3. 
lists the enrichment analysis results of cortical gene expression data. Table S6.4. shows 
the comparison of disease-specific vs. pleiotropic risk loci by various functional and 
genomic features.  
 
Table S7: Tables Related to STAR Methods section “Comparison with other brain-
related traits and diseases” - Relationship between Cross-disorder Genetic Risk 
and other Brain-related Traits and Diseases. Table S7.1. summarizes the genetic 
correlation analysis of the cross-disorder phenotype with other brain-related traits. Table 
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